Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitric Acid SCHEMBL5697160 | 0.98 | CA5A (0.40) | CA5ACA5BTSHRCYP2C19 | |
| SCHEMBL7861963 | 0.93 | TSHR (0.33) | TSHRCYP2C19 | |
| SCHEMBL7861964 | 0.87 | TSHR (0.33) | TSHRCYP2C19 | |
| SCHEMBL10340530 | 0.87 | TSHR (0.33) | TSHRCYP2C19 | |
| SCHEMBL10340531 | 0.87 | TSHR (0.33) | TSHRCYP2C19 | |
| SCHEMBL5697152 | 0.87 | TSHR (0.39) | TSHRCYP2C19 | |
| SCHEMBL28403829 | 0.76 | TSHR (0.36) | TSHRCYP2C19 | |
| Nitric Acid SCHEMBL8206707 | 0.73 | CA5A (0.35) | CA5ACA5BTSHRCYP2C19 | |
| Water SCHEMBL28902130 | 0.73 | TSHR (0.35) | TSHRCYP2C19 | |
| Hydrochloric Acid SCHEMBL26112375 | 0.73 | TSHR (0.35) | TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1705254-A2 | Compositions and methods using platinum for nucleic acid labeling | Stratagene California (US) | 2006-09-27 | — | — | EP | disclosed |
| EP-1373572-B1 | COMPOSITIONS AND METHODS USING PLATINUM COMPOUNDS FOR NUCLEIC ACID LABELING | STRATAGENE CALIFORNIA (US) | 2006-07-26 | — | — | EP | disclosed |
| US-6825330-B2 | A PLATINUM COMPOUND COVELENTLY ATTACHED TO A DETACTABLE MARKER VIA A LINKER (LINKER IS A GROUP JOINING NITROGEN TO A FLUOROPHORE, A CHROMOPHORE, A RADIOLABEL, AN ENZYME OR AN AFFINITY TAG) | STRATAGENE CALIFORNIA | 2004-11-30 | — | — | US | disclosed |
| US-20020165369-A1 | Compositions and methods using platinum compounds for nucleic acid labeling | STRATAGENE | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165369-A1 | Compositions and methods using platinum compounds for nucleic acid labeling | PCNA, CXCR3, APEX1 | CA5A 151/4885CA5B 214/4885TSHR 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.